Impulse control disorders in chronic migraine with medication overuse after onabotulinumtoxinA: A single-center prospective cohort study

[1]  Jieun Lee,et al.  Chronic Migraine Headaches: Role of Smoking and Locus of Control , 2020, SN Comprehensive Clinical Medicine.

[2]  D. Cordato,et al.  Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study , 2019, The Journal of Headache and Pain.

[3]  C. Gaul,et al.  An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study , 2019, The Journal of Headache and Pain.

[4]  R. Lipton,et al.  Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study , 2019, The Journal of Headache and Pain.

[5]  R. Lipton,et al.  Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study , 2019, The Journal of Headache and Pain.

[6]  S. Tepper,et al.  Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[7]  S. Sacco,et al.  Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation , 2018, The Journal of Headache and Pain.

[8]  A. Argyriou,et al.  Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment , 2018, The Journal of Headache and Pain.

[9]  Z. Katsarava,et al.  Medication-overuse headache: a widely recognized entity amidst ongoing debate , 2018, The Journal of Headache and Pain.

[10]  A. Blumenfeld,et al.  Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study , 2018, The Journal of Headache and Pain.

[11]  P. Martelletti.  The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine , 2018, The Journal of Headache and Pain.

[12]  L. Pini,et al.  Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy , 2017, Front. Neurol..

[13]  A. Kocaman,et al.  OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study , 2017, The Journal of Headache and Pain.

[14]  Lorraine A Sanassi.  Botulinum toxin: A lift for chronic migraines , 2016, JAAPA : official journal of the American Academy of Physician Assistants.

[15]  R. Lipton,et al.  Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety , 2015, International journal of general medicine.

[16]  J. Reichenberg,et al.  Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. , 2014, The Journal of clinical psychiatry.

[17]  N. Rosenthal,et al.  Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial. , 2014, Journal of psychiatric research.

[18]  H. Diener,et al.  OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program , 2014 .

[19]  S. Aurora,et al.  OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56‐Week PREEMPT Clinical Program , 2011, Headache.

[20]  P. Calabresi,et al.  Migraine and psychiatric comorbidity: a review of clinical findings , 2011, The Journal of Headache and Pain.

[21]  F. Pierelli,et al.  Drug consumption in medication overuse headache is influenced by brain-derived neurotrophic factor Val66Met polymorphism , 2009, The Journal of Headache and Pain.

[22]  R. Kessler,et al.  The associations between preexisting mental disorders and subsequent onset of chronic headaches: a worldwide epidemiologic perspective. , 2015, The journal of pain : official journal of the American Pain Society.